Clinical Information

Comprehensive clinical data and prescribing information for healthcare professionals

Tinidazole: Clinical Profile

Evidence-based clinical information for prescribing decisions

Drug Classification

  • Class: Nitroimidazole antiprotozoal
  • Mechanism: DNA-damaging agent
  • Spectrum: Broad-spectrum antiprotozoal
  • Route: Oral
  • Availability: Tablet formulation

Pharmacokinetics

  • Absorption: Rapidly absorbed from GI tract
  • Peak Levels: 1-2 hours post-administration
  • Half-life: 12-14 hours
  • Protein Binding: 12%
  • Metabolism: Hepatic
  • Elimination: Renal (60-80%)

Approved Indications

FDA-approved and evidence-based uses

Primary Indications

  • Trichomoniasis: Trichomonas vaginalis infection
  • Giardiasis: Giardia lamblia infection
  • Amebiasis: Entamoeba histolytica infection

Off-Label Uses

  • Balantidium coli infection
  • Blastocystis hominis infection
  • Dientamoeba fragilis infection
  • Anaerobic bacterial infections

Dosage & Administration

Standard dosing regimens for various indications

Trichomoniasis

Adults: 2 g single dose OR 1 g twice daily for 2 days

Children: 50 mg/kg single dose (max 2 g)

Pregnancy: Generally safe in 2nd/3rd trimester

Giardiasis

Adults: 2 g daily for 5-7 days

Children: 50 mg/kg/day for 5-7 days (max 2 g/day)

Alternative: 1 g daily for 3 days

Amebiasis (Intestinal)

Adults: 2 g daily for 3 days

Children: 50 mg/kg/day for 3 days (max 2 g/day)

Note: Follow with luminal agent for asymptomatic cysts

Amebiasis (Extraintestinal)

Adults: 2 g daily for 5-10 days

Children: 50 mg/kg/day for 5-10 days (max 2 g/day)

Note: May require additional therapy

Clinical Efficacy

Evidence-based efficacy data from clinical trials

Trichomoniasis

  • Cure Rate: 90-95%
  • Single Dose Efficacy: 90-95%
  • Symptom Relief: 2-3 days
  • Recurrence Rate: <5%
  • Partner Treatment: Essential

Giardiasis

  • Cure Rate: 90-100%
  • Symptom Relief: 3-5 days
  • Cyst Clearance: 95-100%
  • Recurrence Rate: <2%
  • Immunocompromised: May require longer therapy

Amebiasis (Intestinal)

  • Cure Rate: 90-95%
  • Symptom Relief: 3-7 days
  • Cyst Clearance: 95%+
  • Luminal Agent: Recommended

Amebiasis (Extraintestinal)

  • Cure Rate: 85-95%
  • Abscess Resolution: 7-14 days
  • Combination Therapy: Often needed
  • Drainage: May be required

Adverse Reactions

Incidence and management of side effects

Common Adverse Reactions (>1%)

  • Metallic taste (10-15%)
  • Nausea (5-10%)
  • Headache (3-5%)
  • Anorexia (2-3%)
  • Diarrhea (2-3%)
  • Dizziness (1-2%)

Serious Adverse Reactions (<1%)

  • Seizures
  • Peripheral neuropathy
  • Severe hypersensitivity
  • Hepatotoxicity
  • Hematologic abnormalities
  • Pancreatitis

Drug Interactions

Significant interactions and contraindications

Major Interactions

  • Alcohol: Disulfiram-like reaction
  • Warfarin: Increased anticoagulant effect
  • Lithium: Increased lithium levels
  • Phenobarbital: Decreased tinidazole levels

Moderate Interactions

  • Cimetidine: May increase tinidazole levels
  • Cholestyramine: May reduce absorption
  • Other nitroimidazoles: Additive toxicity

Contraindications

  • Hypersensitivity to nitroimidazoles
  • First trimester pregnancy (relative)
  • Concurrent disulfiram use

Precautions

  • Hepatic impairment: Dose adjustment
  • Renal impairment: Monitor closely
  • CNS disease: Risk of seizures
  • Blood dyscrasias: Baseline labs

Copyright © Taj Pharma. All rights reserved.